151 related articles for article (PubMed ID: 37682503)
1. Clinical Outcomes and Serum B-Cell Maturation Antigen Levels in a Real-World Unselected Population of Newly Diagnosed Multiple Myeloma Patients.
Jew S; Bujarski S; Regidor B; Emamy-Sadr M; Swift R; Eades B; Kim S; Eshaghian S; Berenson JR
Target Oncol; 2023 Sep; 18(5):735-747. PubMed ID: 37682503
[TBL] [Abstract][Full Text] [Related]
2. Use of serum B-cell maturation antigen levels to predict outcomes for myeloma patients treated with ruxolitinib, lenalidomide and methylprednisolone.
Bujarski S; Sutanto C; Spektor TM; To J; Swift RA; Green T; Eades BR; Emamy-Sadr M; Souther E; Berenson JR
Hematol Oncol; 2022 Apr; 40(2):243-248. PubMed ID: 34982491
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
[No Abstract] [Full Text] [Related]
4. Baseline and Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Patients with Relapsed/Refractory Multiple Myeloma Starting New Therapy.
Bujarski S; Udd K; Soof C; Chen H; Spektor TM; Safaie T; Li M; Stern J; Wang C; Xu N; Emamy-Sadr M; Swift R; Rahbari A; Patil S; Souther E; Regidor B; Sutanto C; Berenson JR
Target Oncol; 2021 Jul; 16(4):503-515. PubMed ID: 34097243
[TBL] [Abstract][Full Text] [Related]
5. Soluble B-cell maturation antigen as a monitoring marker for multiple myeloma.
Wiedemann Á; Szita VR; Horváth R; Szederjesi A; Sebő A; Tóth AD; Masszi T; Varga G
Pathol Oncol Res; 2023; 29():1611171. PubMed ID: 37188125
[No Abstract] [Full Text] [Related]
6. Normalization of serum B-cell maturation antigen levels predicts overall survival among multiple myeloma patients starting treatment.
Jew S; Chang T; Bujarski S; Soof C; Chen H; Safaie T; Li M; Sanchez E; Wang C; Spektor TM; Emamy-Sadr M; Swift R; Rahbari A; Patil S; Souther E; Berenson JR
Br J Haematol; 2021 Jan; 192(2):272-280. PubMed ID: 32441777
[TBL] [Abstract][Full Text] [Related]
7. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].
Yang FY; Wang HF; Xia LH; Wang QQ; Qian CJ; He J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):158-165. PubMed ID: 35123620
[TBL] [Abstract][Full Text] [Related]
8. Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life.
Joseph NS; Gupta VA; Wyman S; Graiser M; Kaufman JL; Almaula D; Andrews J; Hofmeister C; Dhodapkar M; Heffner LT; Lonial S; Nooka AK
Transplant Cell Ther; 2022 Feb; 28(2):75.e1-75.e7. PubMed ID: 34626863
[TBL] [Abstract][Full Text] [Related]
9. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Mina R; Musto P; Rota-Scalabrini D; Paris L; Gamberi B; Palmas A; Aquino S; de Fabritiis P; Giuliani N; De Rosa L; Gozzetti A; Cellini C; Bertamini L; Capra A; Oddolo D; Vincelli ID; Ronconi S; Pavone V; Pescosta N; Cea M; Fioritoni F; Ballanti S; Grasso M; Zamagni E; Belotti A; Boccadoro M; Gay F
Lancet Oncol; 2023 Jan; 24(1):64-76. PubMed ID: 36528035
[TBL] [Abstract][Full Text] [Related]
10. Impact of autologous transplantation on survival in patients with newly diagnosed multiple myeloma who have high-risk cytogenetics: A meta-analysis of randomized controlled trials.
Chakraborty R; Siddiqi R; Willson G; Gupta S; Asghar N; Husnain M; Aljama MA; Behera TR; Anwer F; Perrot A; Riaz IB
Cancer; 2022 Jun; 128(12):2288-2297. PubMed ID: 35377484
[TBL] [Abstract][Full Text] [Related]
11. Single-center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation.
Chan H; Phillips M; Maganti M; Farooki S; Piza Rodriguez G; Masih-Khan E; Chen C; Prica A; Reece D; Tiedemann R; Trudel S; Kukreti V
Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):225-234. PubMed ID: 29397346
[TBL] [Abstract][Full Text] [Related]
12. [Expression of sBCMA in Newly Diagnosed Multiple Myeloma Patients and Its Relationship with Prognosis].
Zheng LL; Li B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Aug; 31(4):1108-1112. PubMed ID: 37551484
[TBL] [Abstract][Full Text] [Related]
13. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
14. [Long-term follow-up of multiple myeloma after autologous hematopoietic stem cell transplantation: a single center results].
Sui WW; Zou DH; An G; Yi SH; Deng SH; Huang WY; Wang TY; Li J; Liu H; Fu MW; Lyu R; Liu W; Xu Y; Li ZJ; Zhao YZ; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):499-504. PubMed ID: 28655093
[No Abstract] [Full Text] [Related]
15. Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis.
Piechotta V; Jakob T; Langer P; Monsef I; Scheid C; Estcourt LJ; Ocheni S; Theurich S; Kuhr K; Scheckel B; Adams A; Skoetz N
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31765002
[TBL] [Abstract][Full Text] [Related]
16. Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study.
Fan H; Wang W; Zhang Y; Wang J; Cheng T; Qiu L; Wang X; Xia Z; An G
Cancer Biol Med; 2023 Jan; 20(1):77-87. PubMed ID: 36647781
[TBL] [Abstract][Full Text] [Related]
17. [The prognostic value of dynamic minimal residual disease after autologous hematopoietic stem cell transplantation in patients with multiple myeloma in novel-agent era].
Yang GZ; Wang GR; Wang HJ; Zhang YR; Wu Y; Li YC; Liu AJ; Leng Y; Gao W; Chen WM
Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(30):2345-2350. PubMed ID: 35970792
[No Abstract] [Full Text] [Related]
18. Treatment Pattern and Outcomes in Newly Diagnosed Multiple Myeloma Patients Who Did Not Receive Autologous Stem Cell Transplantation: A Real-World Observational Study : Treatment pattern and outcomes in patients with multiple myeloma.
He J; Schmerold L; Van Rampelbergh R; Qiu L; Potluri R; Dasgupta A; Li L; Li Y; Hu P; Nemat S; Smugar SS; Zeltzer P; Appiani C; Li Q; Mehra M; Richarz U
Adv Ther; 2021 Jan; 38(1):640-659. PubMed ID: 33211297
[TBL] [Abstract][Full Text] [Related]
19. Treatment patterns and clinical outcomes in high-risk newly diagnosed multiple myeloma patients carrying the 17p deletion: An observational multi-center retrospective study.
Cohen YC; Saranga A; Gatt ME; Lavi N; Ganzel C; Magen H; Avivi I; Tadmor T; Suriu C; Jarchowsky Dolberg O; Papushado A; Trestman S; Ram R
Am J Hematol; 2018 Jun; 93(6):810-815. PubMed ID: 29603773
[TBL] [Abstract][Full Text] [Related]
20. Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation.
Afrough A; Pasvolsky O; Ma J; Srour S; Bashir Q; Saini N; Hosing C; Popat UR; Kebriaei P; Delgado R; Ullah MR; Murphy R; Manasanch EE; Lee HC; Kaufman GP; Patel KK; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
Transplant Cell Ther; 2022 Jun; 28(6):307.e1-307.e8. PubMed ID: 35331973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
